Takeda Pharmaceutical Company Limited and TiGenix NV today announced new data from the Phase 3 ADMIRE-CD clinical trial, which indicated that investigational compound Cx601, a suspension of allogeneic adipose-derived stem cells , maintained long-term remission of treatment refractory complex perianal fistulas in patients with Crohn’s disease over 52 weeks.[1] Results were presented at the 12th Congress of the European Crohn’s and Colitis Organisation .